OneDigital Investment Advisors LLC Buys 6,800 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

OneDigital Investment Advisors LLC increased its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 51.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,000 shares of the company’s stock after buying an additional 6,800 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Inozyme Pharma were worth $105,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Inozyme Pharma by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock worth $18,530,000 after acquiring an additional 33,998 shares in the last quarter. Kennedy Capital Management LLC grew its position in Inozyme Pharma by 52.2% in the 1st quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock worth $3,352,000 after purchasing an additional 150,120 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Inozyme Pharma in the 2nd quarter valued at about $76,000. Bank of New York Mellon Corp increased its stake in Inozyme Pharma by 16.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock valued at $851,000 after buying an additional 26,464 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Inozyme Pharma by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after buying an additional 13,867 shares in the last quarter. 88.30% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Stifel Nicolaus assumed coverage on Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Jefferies Financial Group reissued a “buy” rating and issued a $17.00 price target (up from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Inozyme Pharma in a report on Wednesday, November 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $12.00 target price (down from $15.00) on shares of Inozyme Pharma in a research note on Tuesday, November 5th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma presently has an average rating of “Buy” and a consensus price target of $15.71.

Inozyme Pharma Trading Up 4.5 %

Shares of INZY opened at $2.81 on Friday. The firm has a market cap of $180.51 million, a P/E ratio of -1.80 and a beta of 1.54. Inozyme Pharma, Inc. has a fifty-two week low of $2.61 and a fifty-two week high of $7.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The business has a 50-day moving average of $4.66 and a 200 day moving average of $4.83.

Inozyme Pharma (NASDAQ:INZY) last posted its earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. As a group, research analysts forecast that Inozyme Pharma, Inc. will post -1.59 EPS for the current year.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.